The Drug-Induced Cardiotoxicity Website and App

Frequency - Incidence

Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.g

Pleural/pericardial effusion, ANA positive (DI lupus)

Publications

Sahyouni M, Deal A, Castles H, Maranto M, Greenfield B, Regmi S, Paudyal S, Rofael M

Large Pericardial Effusion as a Manifestation of Overlapping Hydralazine-Induced Lupus and ANCA Vasculitis.

JACC. Case reports. 2026:109878

Jerome R, Randhawa JS, Badran S, Li S, Mohammadi N

Drug-Induced Systemic Lupus Erythematosus: A Rare Presentation of Hydralazine-Induced Lupus.

Cureus. 2024;16(10):e72069

SPAULDING WB

Dangers in the use of some potent drugs.

Canadian Medical Association journal. 1962;87(24):1275-81

DUSTAN HP, TAYLOR RD, CORCORAN AC

Rheumatic and febrile syndrome during prolonged hydralazine treatment.

Journal of the American Medical Association. 1954;154(1):23-9